Philadelphia, PA, May 25, 2012 --(PR.com
)-- On Tuesday and Wednesday, January 10th and 11th of 2012, TTC, llc, provider of industry-wide cost benchmarking tools, sponsored the ‘2nd Annual State of Clinical Development Cost’ Conference hosted by USciences. This conference was widely attended by drug development professionals, academics, and students and it focused on the industry’s best practices, standard of care trends, difficult countries for budgeting, Pharma’s future challenges, and much more.
The proceeds from this conference are being donated to a research fund that USciences uses for research on prevalent topics and areas of concern addressed by attendees.
TTC conference hosted two key-note speakers Dr. Peter Aurup, Head of Global Clinical Trials Operations, Merck and Dr. Peter Sharma, Vice President and Head of Clinical Research & Precision Medicine, Pfizer on “Future Challenges for Big Pharma” and “Current Industry Practices.”
Dr. Harold Glass presented on the current industry challenges and their severity. These challenges include how the era of abundance is over and is transitioning into an era of scarcity for R&D productivity and drug sales. Throughout his presentation he discussed the sources of drug development costs and ways to more effectively manage them.
The conference hosted multiple panels and one breakout session:
· During the panel ‘Standard of Care – Trends and Case Studies’, one attendee had said “This topic generated a lot of interactive discussion. I noticed that the discussion spilled over into the lunch break, which was terrific.”
· On R&D globalization, “I liked it; it is a topic that keeps me up at night… Please make sure if you continue this topic in the future that you build upon it and just not repeat it. The ideas presented are current today, but in this fast changing world, will be outdated in a year if you cannot build on it.” – The CRO panel discussion.
· “Very informative, data driven look at the trends in industry, asked a lot of questions that we in industry have been finding difficult to formulate. Would be interested in his slides.” - discussing Dr. Harold Glass and his presentation ‘The Annual State of Clinical Development Costs’
· Another attendee had this to say about the fourth panel on ‘Late Phase Study Planning and Budgeting,’ “It was interesting to consider the many issues that are specific to late phase studies.”
· Students from USciences were able to attend this conference as well. “From a student’s perspective, I was able to learn that there are so many different aspects that contribute to this industry and we are beginning to realize that there are many issues that need to be addressed within each.”
For more information on clinical trials visit http://www.ttc-llc.com or call us at 215-243-4103.